Navigation Links
BioMarin Announces Third Quarter 2008 Financial Results
Date:10/28/2008

,907 $47,982

Current portion of acquisition obligation,

net of discount 6,309 71,158

Deferred revenue 5,327 1,443

Other current liabilities - 152

Total current liabilities 61,543 120,735

Convertible debt 497,375 497,240

Long-term portion of acquisition obligation,

net of discount 66,553 -

Other long-term liabilities 2,082 3,162

Total liabilities 627,553 621,137

Stockholders' equity:

Common stock, $0.001 par value: 250,000,000

shares authorized at December 31, 2007 and

September 30, 2008; 97,114,159 and 99,691,581

shares issued and outstanding at December 31,

2007 and September 30, 2008, respectively 97 100

Additional paid-in capital 794,917 841,657

Company common stock held by deferred

compensation plan - (939)

Accumulated other comprehensive income (loss) 139 (1,818)

Accumulated deficit (607,427) (601,102)

Total stockholders' equity 187,726 237,901

Total liabilities and stockholders' equity $815,279 $859,038

(1) December 31, 2007 balances were derived from the audited consolidated

financials.

BIOMARIN PHARMACEUTICAL INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS

For the Three and Nine Months Ended September 30, 2007 and 2008

(In thousands, except for per share data, unaudited)

Three Mon
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. BioMarin Corrects Information Included in Bloomberg Article
2. BioMarin to Present at the Merrill Lynch Global Pharmaceutical Conference
3. BioMarin to Present at the Morgan Stanley Global Healthcare Conference
4. BioMarin to Present at the Citi Biotech Day
5. BioMarin Announces Roll-Out of National PKU Registry
6. BioMarin to Host Second Quarter 2008 Financial Results Conference Call and Webcast on Tuesday, August 5 at 5:00 p.m. ET (23:00 CET)
7. BioMarin to Present at the Collins Stewart Growth Conference
8. SciQuest Announces Newest Life Sciences Customer; BioMarin Pharmaceutical Drives Spending Effectiveness with Automated, Intuitive Procurement
9. BioMarin Announces Program for ERT for Treatment of MPS IVA - Morquio A Syndrome
10. BioMarin to Host Research and Development Day June 5th
11. BioMarin to Present at the Bank of America Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Opertech Bio, Inc., a company ... effective approach to sensory evaluation, today announced the ... U.S. Patent and Trademark Office, encompassing high-throughput sensory ... “Opertech’s taste evaluation technology called Microtiter Operant Gustometer ... system for rapid characterization of taste sensory properties,” ...
(Date:9/2/2014)... 2014  Synthetic Biologics, Inc. (NYSE MKT: SYN), ... candidates targeting specific pathogens that cause serious infections ... final preclinical toxicology study of SYN-004. Per U.S. ... study was required to move the Company,s lead ... devastating effects of Clostridium difficile (C. difficile), ...
(Date:9/2/2014)... 2014 Culot brings life science ... management services  BioData, producer of Labguru, the ... announce the appointment of Louis Culot as ... VP Marketing and Business Development at BioDiscovery Inc., developer ... applications. Previously, Culot worked for 17 years ...
(Date:9/1/2014)... The Collaborative R&D Terms and ... comprehensive understanding and unprecedented access to the collaborative ... worlds leading life science companies. , The report ... and why companies enter collaborative R&D deals. , ... deals terms provides critical insight into the negotiation ...
Breaking Biology Technology:Opertech Bio Receives U.S. Patent for High-Throughput Taste Evaluation Technology 2Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 2Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 3Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 4Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 5Louis Culot Appointed as BioData's CEO 2Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics Industry Analysis, Size, Share, Growth, Trends And Forecast Research Report by Researchmoz.us 2Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics Industry Analysis, Size, Share, Growth, Trends And Forecast Research Report by Researchmoz.us 3Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics Industry Analysis, Size, Share, Growth, Trends And Forecast Research Report by Researchmoz.us 4
... Switzerland, October 5, 2011 Debiopharm Group™ ... on drug development and companion diagnostics, today presented the ... Cancer Center Research Institute in Tokyo, for his basic ... genes, and to Doctor Mineo Kurokawa from the University ...
... 4, 2011 The VENTANA anti-Helicobacter pylori (SP48) Rabbit ... H. pylori antibody to receive 510(k) ... by Ventana Medical Systems, Inc. (Ventana), a member of ... used in immunohistochemical (IHC) staining, aids in the detection ...
... JACKSONVILLE, Fla., Oct. 4, 2011 MSC Care ... and services to post-discharge and post-injury workers, compensation ... Integrated Healthcare Services, a national company also focused ... unique and comprehensive surgical implant cost management solution, ...
Cached Biology Technology:The Japanese Cancer Association and Debiopharm Group™ Present Doctors Arakawa and Kurokawa With the 2011 'JCA-Mauvernay Award' for Their Innovative and Outstanding Research in the Field of Cancer 2The Japanese Cancer Association and Debiopharm Group™ Present Doctors Arakawa and Kurokawa With the 2011 'JCA-Mauvernay Award' for Their Innovative and Outstanding Research in the Field of Cancer 3Ventana Medical Systems, Inc. Receives First FDA 510(k) Clearance for H. pylori Antibody 2Ventana Medical Systems, Inc. Receives First FDA 510(k) Clearance for H. pylori Antibody 3MSC to Offer Surgical Implant Cost Management Solution through Acquisition of Integrated Healthcare Services 2
(Date:9/2/2014)... From AGU,s blogs: Earthquake rupture through a U.S. suburb ... University of California Davis in the hours and days ... helping scientists understand why the earthquake caused so much ... The Trembling Earth blog, hosted by the American Geophysical ... Future Mars Rovers: The Next Places to Direct Our ...
(Date:9/2/2014)... September 3, The Field Museum will present the prestigious ... of his commitment to biodiversity conservation awareness. The Parker/Gentry ... an outstanding individual, team or organization whose efforts have ... natural heritage and whose actions can serve as a ... of Mongabay.com, an environmental science and conservation news website ...
(Date:9/2/2014)... Konservat-Lagersttte of lithographic limestone is well known as ... from that area (for example, Archaeopteryx). Now, for ... in the French equivalent of these outcrops - ... oldest known water treader. , Despite the abundance ... fossils have been obtained from the Late Kimmeridgian ...
Breaking Biology News(10 mins):This week From AGU: California earthquake, future Mars rovers, models underestimate ozone 2Exceptionally well preserved insect fossils from the Rhône Valley 2
... to support the theory that old cells help make ... that as these animals age, the number of aging ... cells lose their ability to divide, a state known ... advanced online edition of Science, is the first to ...
... the journal Genome Research that large segments ... mobile DNA elements called transposons. The locations of ... are enriched in genes crucial for the regulation of ... DNA sequences that have the capacity to move from ...
... SIDS (sudden infant death syndrome) in African Americans can be ... deaths result from a common genetic variation that increases an ... of environmental stress, a research team based at the University ... Journal of Clinical Investigation. , Children with two copies ...
Cached Biology News:Aging cells, aging body: Fresh evidence for a connection 2Where 'jumping genes' fear to tread 2Gene variation increases SIDS risk in African Americans 2Gene variation increases SIDS risk in African Americans 3
biotin-4-fluorescein...
Human IL-17D Affinity Purified Polyclonal Ab...
Agar, 5 lb. Bacteriological.Moisture: < 10%, ash: < 6.5%. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
BBS/Glycerol/Casein Block and Diluent - 10X Concentrate, 1 L...
Biology Products: